Recap: argenx Q1 Earnings

 

Shares of argenx ARGX were unchanged after the company reported Q1 results.

Quarterly Results

Earnings per share increased 60.68% year over year to ($0.81), which may not compare to the estimate of ($3.13).

Revenue of $158,155,000 rose by 647.92% from the same period last year, which beat the estimate of $27,230,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 14, 2021

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.argenx.com%2F&eventid=3079995&sessionid=1&key=2279190C6045554D71EB1B97566B8127&regTag=&V2=false&sourcepage=register

Recent Stock Performance

Company's 52-week high was at $382.15

Company's 52-week low was at $141.26

Price action over last quarter: down 9.83%

Company Profile

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!